Impact	O
of	O
systemic	O
alitretinoin	B:C0281666
treatment	B:C0087111
on	O
skin	B:C2246986
barrier	I:C2246986
gene	B:C0017262
and	O
protein	B:C1171362
expression	I:C1171362
in	O
patients	O
with	O
chronic	B:C1276092
hand	I:C1276092
eczema	I:C1276092
.	O

Chronic	B:C1276092
hand	I:C1276092
eczema	I:C1276092
(	O
Chronic	B:C1276092
hand	I:C1276092
eczema	I:C1276092
)	O
is	O
a	O
common	O
inflammatory	B:C3875321
skin	I:C3875321
disease	I:C3875321
that	O
affects	O
approximately	O
10	O
%	O
of	O
the	O
population	B:C1257890
.	O

Systemic	O
alitretinoin	B:C0281666
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
patients	O
with	O
Chronic	B:C1276092
hand	I:C1276092
eczema	I:C1276092
who	O
are	O
refractory	O
to	O
topical	B:C0304604
corticosteroids	I:C0304604
.	O

To	O
analyse	O
the	O
impact	O
of	O
alitretinoin	B:C0281666
on	O
the	O
skin	B:C2246986
barrier	I:C2246986
genes	B:C0017337
and	O
protein	B:C1171362
expression	I:C1171362
in	O
the	O
skin	B:C0037284
lesions	I:C0037284
of	O
patients	O
with	O
Chronic	B:C1276092
hand	I:C1276092
eczema	I:C1276092
.	O

Fifteen	O
patients	O
with	O
Chronic	B:C1276092
hand	I:C1276092
eczema	I:C1276092
were	O
treated	B:C0332293
with	I:C0332293
30	O
mg	O
daily	O
of	O
alitretinoin	B:C0281666
for	O
up	O
to	O
27	O
weeks	O
.	O

Skin	B:C0150866
biopsies	I:C0150866
from	O
all	O
the	O
patients	O
were	O
evaluated	B:C0220825
before	O
and	O
after	O
therapy	B:C0087111
for	O
the	O
expression	B:C1171362
of	O
Ki-67	B:C0208804
,	O
various	O
skin	B:C2246986
barrier	I:C2246986
genes	B:C0017337
and	O
thymic	B:C0762640
stromal	I:C0762640
lymphopoietin	I:C0762640
(	O
thymic	B:C0762640
stromal	I:C0762640
lymphopoietin	I:C0762640
)	O
by	O
real	B:C3179034
-	I:C3179034
time	I:C3179034
quantitative	I:C3179034
polymerase	I:C3179034
chain	I:C3179034
reaction	I:C3179034
and	O
immunohistochemistry	B:C0021044
.	O

After	O
alitretinoin	B:C0281666
application	O
,	O
an	O
improvement	O
in	O
the	O
clinical	O
severity	O
of	O
Chronic	B:C1276092
hand	I:C1276092
eczema	I:C1276092
was	O
observed	O
in	O
the	O
majority	O
of	O
patients	O
.	O

Analysis	B:C0936012
of	O
skin	B:C0150866
biopsies	I:C0150866
before	O
treatment	B:C0087111
showed	O
a	O
significant	O
increase	O
in	O
Ki-67	B:C1334508
-	O
positive	B:C1514241
cells	B:C0007634
in	O
the	O
suprabasal	B:C0243092
layer	I:C0243092
and	O
a	O
dysregulated	B:C0017263
expression	I:C0017263
of	O
various	O
skin	B:C2246986
barrier	I:C2246986
genes	B:C0017337
,	O
such	O
as	O
claudin	B:C1413460
1	I:C1413460
,	O
loricrin	B:C1416897
,	O
filaggrin	B:C1414633
and	O
cytokeratin	B:C1416714
10	I:C1416714
,	O
which	O
were	O
normalized	B:C1882115
after	O
treatment	B:C0087111
.	O

thymic	B:C0762640
stromal	I:C0762640
lymphopoietin	I:C0762640
was	O
significantly	O
upregulated	B:C0041904
in	O
patients	O
with	O
Chronic	B:C1276092
hand	I:C1276092
eczema	I:C1276092
and	O
also	O
normalized	B:C1882115
after	O
alitretinoin	B:C0281666
treatment	B:C0087111
and	O
negatively	B:C1513916
correlated	O
with	O
filaggrin	B:C0117738
.	O

Our	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
barrier	O
genes	B:C0017337
and	O
proteins	B:C0033684
was	O
normalized	B:C1882115
following	O
treatment	B:C0087111
with	O
alitretinoin	B:C0281666
in	O
patients	O
with	O
Chronic	B:C1276092
hand	I:C1276092
eczema	I:C1276092
.	O

The	O
change	O
in	O
expression	B:C0017262
levels	O
of	O
these	O
genes	B:C0017337
correlated	O
with	O
the	O
clinical	O
efficacy	O
,	O
suggesting	O
that	O
alitretinoin	B:C0281666
exhibits	O
a	O
disease	B:C0012634
-	O
modifying	O
activity	O
.	O

thymic	B:C0762640
stromal	I:C0762640
lymphopoietin	I:C0762640
is	O
upregulated	B:C0041904
in	O
Chronic	B:C1276092
hand	I:C1276092
eczema	I:C1276092
and	O
seems	O
to	O
counteract	O
filaggrin	B:C0117738
expression	B:C1171362
in	O
the	O
skin	B:C1123023
.	O

